Research Topics
| L PerrinSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approachDimitrios Paraskevis
Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
Retrovirology 6:49. 2009..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic featuresCaroline Tapparel
Central Laboratory of Virology, Division of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland
BMC Genomics 8:224. 2007..The lack of HRV full-length genome sequences and the absence of analysis comparing picornaviruses at the whole genome level limit our knowledge of the genomic features supporting these differences...
Therapeutic vaccination in primary HIV infection, the Quest trialLuc Perrin
Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
Vaccine 20:2004-6. 2002
Travel and the spread of HIV-1 genetic variantsLuc Perrin
Laboratory of Virology, Division of Infectious Diseases, University of Geneva, Switzerland
Lancet Infect Dis 3:22-7. 2003..The spreading of HIV-1 variants has implications for diagnostic, treatment, and vaccine development...
Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapyL Perrin
AIDS Centre, Department of Otho Rhino Laryngology, Geneva University Hospital, Switzerland
J Infect Dis 177:1497-501. 1998..Six subjects had both detectable plasma viremia and evidence of HIV-1 RNA in lymphoid tissue. The results indicate that absence of detectable HIV RNA in lymphoid tissue is associated with viremia levels of HIV-1 RNA <20 copies/mL...
Primary HIV infectionL Perrin
Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
Antivir Ther 4:13-8. 1999..In clinical practice, adherence is closely linked to the patient's commitment, which is the key parameter for treatment decision...
Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation modelF Negro
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
J Hepatol 29:1-11. 1998....
Zidovudine plus didanosine in primary HIV-1 infectionL Perrin
Laboratory of Virology, Geneva University Hospital, Switzerland
Antivir Ther 2:5-11. 1997..These data suggest a higher efficacy of combined therapy compared with zidovudine monotherapy in PHI patients and indicate that control of viraemia for at least 1 year is achievable in PHI patients...
Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patientsS Yerly
Central Laboratory of Virology, Geneva University Hospital, Switzerland
Antivir Ther 1:167-71. 1996..03). These data suggest that there was a better initial CD4 response to didanosine therapy in patients with HIV without the mutation at codon 215, but that this response did not translate into increased survival...
Nosocomial outbreak of multiple bloodborne viral infectionsS Yerly
Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
J Infect Dis 184:369-72. 2001..HIV and HCV genotypic analyses identified a HIV monophyletic group, whereas 4 clusters of HCV sequences were identified. To our knowledge, this is the largest documented outbreak of nosocomial HIV transmission...
IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantationF Negro
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
J Med Virol 56:224-9. 1998..In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance...
Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavirS Yerly
Laboratory of Virology, University Hospital, Geneva, Switzerland
Antivir Ther 6:185-9. 2001..In nelfinavir subjects, 30N was the only primary mutation whereas isolated or combined 82A/T and 461/L mutations were detected in indinavir subjects...
Acute HIV infection: impact on the spread of HIV and transmission of drug resistanceS Yerly
University Hospital of Geneva, 1211 Geneva 14, Switzerland
AIDS 15:2287-92. 2001....
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 proteinS Peters
Division of Infectious Diseases, University Hospital, Lausanne, Switzerland
J Virol 75:9644-53. 2001....
Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon aloneF Negro
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
J Hepatol 29:369-74. 1998..Ofloxacin, a quinolone antibiotic, was recently shown to increase the primary response rate to alpha-interferon treatment of chronic hepatitis C...
[Neuromyelitis optica/Devic's syndrome: new perspectives]P H Lalive
Service de Neurologie, Laboratoire de Neuroimmunologie, HUG, 1211 Geneve 14
Rev Med Suisse 3:950-5. 2007..According to this recent advance, early diagnostic and specific treatment targeting the humoral response should be considered...
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]S Yerly
Laboratoire de Virologie, Hôptal Universitaire de Genève
Schweiz Med Wochenschr 129:319-22. 1999..The new screening assay was positive before a third-generation anti-HIV screening assay gave positive results in 14/34 patients (41%). Using the DUO assay, the mean reduction of the window period was 4 days...
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected childrenChristoph Rudin
Division of Infectious Diseases, University Children s Hospital, Basel, Switzerland
Pediatr Infect Dis J 27:431-7. 2008..To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced, initially protease inhibitor (PI)-naive, human immunodeficiency virus (HIV)-1-infected children...
Human herpesvirus-6 variant A encephalomyelitisC Pot
Department of Neurosciences, Division of Neurology, Geneva University Hospital, Micheli-du-Crest 24, 1211 Geneva 14, Switzerland
Neurology 70:974-6. 2008
Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infectionAnnelie Tjernlund
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
AIDS 20:11-9. 2006..Leukemia inhibitor factor (LIF) is thought to play a substantial role in protecting CD4 T cells in lymphoid tissues (LT) from infection by HIV-1...
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell lossJorg Schupbach
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
J Acquir Immune Defic Syndr 40:250-6. 2005..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
J Infect Dis 192:958-66. 2005..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated...
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infectionSabine Kinloch-de Loes
Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 192:607-17. 2005..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology surveySabine Yerly
Laboratory of Virology, University of Geneva Hospitals, Geneva, Switzerland
AIDS 21:2223-9. 2007..Representative prevalence data of transmitted drug-resistant HIV-1 are essential to establish accurate guidelines addressing resistance testing and first-line treatments...
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapyGilbert R Kaufmann
Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
Clin Infect Dis 41:361-72. 2005..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimenValerie Martinez
Service de Dermatologie, Hopital Tarnier Cochin, 89, rue d Assas, 75006 Paris, France
AIDS 19:1065-9. 2005..Risk factors associated with intermittent viraemia and its impact in patients treated by non-nucleoside-reverse-transcriptase-inhibitor-based (NNRTI) regimen need to be evaluated...
Clinical performance of the LCx HCV RNA quantitative assayRasa Bertuzis
Abbott Laboratories, D99G AP20, 100 Abbott Park Road, Abbott Park, IL 60064-6015, USA
J Virol Methods 123:171-8. 2005..0 specimen results were within 1 log, as were 85.6% (237/277) of paired Roche Monitor 2.0 and Bayer specimen results. These data demonstrate that the LCx assay may be used for quantitation of HCV RNA in HCV-infected individuals...
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineMilos Opravil
AIDS 18:2213-5. 2004
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patientsSamir Vora
Laboratory of Virology, Geneva University Hospital, Switzerland
AIDS 20:35-40. 2006..CONCLUSIONS: The occurrence of three of the eight mutations in the ATV/RTV genotypic resistance score predicted a clinically identifiable reduced response in patients...
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04-614, 3584 CX Utrecht, The Netherlands
J Acquir Immune Defic Syndr 41:352-60. 2006..Because of differences in minor protease substitutions, protease inhibitor resistance could be enhanced in particular subtypes once the relevant major substitutions are selected...
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen typesViktor von Wyl
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
Arch Intern Med 167:1782-90. 2007..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapyBarbara Weiser
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA
AIDS 22:469-79. 2008..Although combination antiretroviral therapy (cART) dramatically reduces rates of AIDS and death, a minority of patients experience clinical disease progression during treatment...
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen
Department of Infectious Diseases, University Medical Centre, Besancon, France
Clin Infect Dis 45:381-90. 2007..Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit...
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreakTulio de Oliveira
Department of Zoology, University of Oxford, Oxford OX1 3PS, UK
Nature 444:836-7. 2006....
HIV viral load monitoring in resource-limited regions: optional or necessary?Alexandra Calmy
Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
Clin Infect Dis 44:128-34. 2007..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
Chronic rhinoviral infection in lung transplant recipientsLaurent Kaiser
Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, Switzerland
Am J Respir Crit Care Med 174:1392-9. 2006..Lung transplant recipients are particularly at risk of complications from rhinovirus, the most frequent respiratory virus circulating in the community...
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialJintanat Ananworanich
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
Lancet 368:459-65. 2006..Treatment-related adverse events were more frequent with continuous treatment, but low CD4 counts and minor manifestations of HIV infection were more frequent with scheduled treatment interruption...
Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patientsOlle Karlström
Divisions of Infectious Diseases, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Infect Dis 38:371-4. 2006..Using a highly sensitive method, NFV was detected and quantified in the CSF, although at low values, which could have contributed to the high anti-HIV-1 efficacy of the therapy seen in our subjects...
Stable virulence levels in the HIV epidemic of Switzerland over two decadesViktor Müller
Bioinformatics Group, Department of Plant Taxonomy and Ecology, Eotvos Lorand University, Budapest, Hungary
AIDS 20:889-94. 2006..To determine whether the virulence of HIV-1 has been changing since its introduction into Switzerland...
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20Anne Genevieve Marcelin
Pitie Salpetriere Hospital, Paris, France
AIDS 18:1340-2. 2004..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infectionRichard Tilling
Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, UK
AIDS 16:589-96. 2002....
Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assayKarine Hadaya
Division of Infectious Diseases, University Hospitals of Geneva, 1211 Geneva 14, Switzerland
J Clin Microbiol 41:3757-64. 2003..This test could improve the monitoring of CMV infection or reactivation in renal transplant recipients...
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAARTCatherine Fagard
Divisions of Infectious Diseases, University Hospital, Geneva, Geneva, Switzerland
AIDS 17:1487-92. 2003..A better understanding of the underlying mechanism(s) may help to identify synergistic treatment targets and improved administration protocols to enhance control of chronic HIV infection...
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcriptsBastien Mangeat
Department of Genetics and Microbiology, University of Geneva, 1211 Geneva 4, Switzerland
Nature 424:99-103. 2003..We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens...
A prospective trial of structured treatment interruptions in human immunodeficiency virus infectionCatherine Fagard
Division of Infectious Diseases, Geneva Unmiversity Hospital, 1211 Geneva 14, Switzerland
Arch Intern Med 163:1220-6. 2003..Treatment interruptions did not provoke clinical complications, and there was little drug resistance. Comparative trials will have to show what benefit, if any, is associated with intermittent, as opposed to continuous treatment...
Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus loadAnnette Oxenius
Nuffield Department of Medicine, John Radcliffe Hospital and Peter Medawar Building for Pathogen Research, Oxford, UK
AIDS 16:2317-22. 2002..CONCLUSION: These findings identify a quantitative immune associate of host-virus interactions in established HIV-1 infection...
Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assayLaurent Kaiser
Division of Infectious Diseases Division of Hematology Division of Oncology, University Hospital of Geneva, Geneva, Switzerland
J Clin Microbiol 40:4251-5. 2002..01). This assay improved the monitoring of CMV infection or reactivation in hematopoietic allogeneic stem cell recipients...
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionAnnette Oxenius
Nuffield Department of Medicine, John Radcliffe Hospital and Peter Medawar Building for Pathogen Research, Oxford OX1 3SY, UK
Proc Natl Acad Sci U S A 99:13747-52. 2002....
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapyGilbert Greub
University Hospital, Lausanne, Switzerland
AIDS 16:1967-9. 2002
A patient with HIV-1 superinfectionStephanie Jost
Division of Infectious Diseases, University of Geneva, Geneva
N Engl J Med 347:731-6. 2002
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infectionAlexandre Harari
Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
Blood 100:1381-7. 2002..These results advance the characterization of antiviral memory CD4 T-cell response and the delineation of the potential mechanisms that likely prevent the generation of a robust CD4 T-cell immune response during primary infection...
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infectionJan Andersson
Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
J Infect Dis 185:1355-8. 2002..This suggests that mechanisms inhibiting CTL-mediated cytotoxicity are operative in lymphoid tissue early in the course of HIV infection...
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infectionMilos Opravil
Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
J Infect Dis 185:1251-60. 2002....
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort StudyGilbert R Kaufmann
Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
Arch Intern Med 163:2187-95. 2003..Treatment interruptions, a poor virologic response, and older age were the major factors negatively affecting the recovery of CD4 T lymphocytes...
Drug resistance mutations during structured treatment interruptionsSabine Yerly
Laboratory of Virology, Geneva University Hospital, Switzerland
Antivir Ther 8:411-5. 2003..55-fold higher in patients with the M184V/I mutation than in patients without detectable mutation (P=0.007). CONCLUSIONS: The M184V/I mutation is frequently selected during repeated treatment interruptions...
Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptionsSabine Yerly
AIDS 18:1951-3. 2004....
Infrequent transmission of HIV-1 drug-resistant variantsSabine Yerly
Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland
Antivir Ther 9:375-84. 2004..These data suggest that drug-resistant variants and in particular multidrug-resistant variants have a substantially reduced transmission capacity...
Cytomegalovirus quantification in plasma by an automated real-time PCR assaySabine Yerly
Laboratory of Virology, University of Geneva Hospitals, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
J Clin Virol 38:298-303. 2007..Sensitive quantitation of cytomegalovirus (CMV) DNA in blood is helpful for the diagnosis of CMV infection or reactivation and the monitoring of transplanted patients...
HIV-1 co/super-infection in intravenous drug usersSabine Yerly
AIDS 18:1413-21. 2004..In chronically infected IVDUs super-infection may be transient and may occur in patients controlling efficiently HIV infection by the initial strain...
Drug resistance mutations: yes but where?Luc Perrin
AIDS 18:1201-2. 2004
Prevalence of human T-cell leukemia virus types I and II in SwitzerlandJürg Böni
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
J Med Virol 72:328-37. 2004..The finding of low HTLV-I/II prevalence among Swiss blood donors and containment of HTLV-I/II infection within known risk-groups does not support initiation of HTLV-I/II screening for Swiss blood, tissue, and organ donations...
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infectionGilbert R Kaufmann
Division of Infectious Diseases, University Hospital, Basel, Switzerland
Antivir Ther 9:263-74. 2004..However, early virological failure increases significantly the risk of subsequent unfavourable virological responses. The choice of a potent initial antiretroviral drug regimen is therefore critical...
Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDSPhilippe Vanhems
Laboratory of Epidemiology and Public Health, INSERM U271, Universite Claude Bernard, Edouard Herriot Hospital, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France
J Acquir Immune Defic Syndr 32:542-4. 2003..1-8.1, P < 0.03 to P < 0.001). Pathogenetic mechanisms involved in the incubation of ARS features may be associated with progression to AIDS...
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infectionKarin Lore
Division of Clinical Virology, Department of Microbiology, Pathology and Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
AIDS 16:683-92. 2002..Dendritic cells (DC) are target cells for HIV-1 and play a key role in antigen presentation and activation of T cells...
HIV-1 and HCV infections among antibody-negative blood donorsJosip Begovac
N Engl J Med 351:2232-5; author reply 2232-5. 2004
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDSAlmut Scherer
Zoology Department, Oxford University, South Parks Road, Oxford OX1 3PS, United Kingdom
Proc Natl Acad Sci U S A 101:12266-70. 2004..These data provide an immunological mechanism to explain HLA-related risk of progression to AIDS and emphasize the central role of viral evolution in the pathogenesis of HIV...
The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell deathJean Daniel Lelievre
INSERM U421, Faculte de Medecine Henri Mondor, Creteil, France
AIDS Res Hum Retroviruses 20:1230-43. 2004..Our data indicate that the density of chemokine receptors expressed on CD4(+) T cells may be a critical parameters for the cytopathic effect of HIV strains and may have major impact on CD4 T cell depletion during HAART...
The incubation period of acute retroviral syndrome as a multistep process: a parametric survival analysisPhilippe Vanhems
Laboratory of Epidemiology and Public Health, INSERM U271, Universite Claude Bernard, and Epidemiology Unit, Edouard Herriot Hospital, Lyon, France
J Acquir Immune Defic Syndr 37:1529-33. 2004....
Parallel and overlapping HIV and bloodborne hepatitis epidemics in AfricaDavid Gisselquist
Hershey, Pennsylvania 17033, USA
Int J STD AIDS 15:145-52. 2004..Across these cohorts, there is a trend for HCV prevalence to increase with HIV, though much of the variance is unexplained. For 25 cohorts with sufficient data, the median relative risk for HCV infection for persons with HIV is 1.52...
Amplicon sequencing and improved detection of human rhinovirus in respiratory samplesChristelle Deffernez
Central Laboratory of Virology, Division of Infectious Diseases, Department of Internal Medicine, University Hospitals of Geneva, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
J Clin Microbiol 42:3212-8. 2004..By sequencing the 5' noncoding regions of rhinoviruses recovered from clinical specimens, we designed probes that could specifically detect rhinovirus...
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and agePhilippe Vanhems
Laboratoire d épidémiologie et de santé publique, and INSERM Unit 271, Faculte de Medecine, Universite Claude Bernard, et Hôpital Edouard Herriot, Lyon, France
J Acquir Immune Defic Syndr 31:318-21. 2002..52%, p=.01). Genital ulcerations were present only in cases of sexual exposure to HIV. Injecting drug users had or reported symptoms associated with the ARS less frequently than persons acquiring HIV via sexual transmission...
Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impactJorge Garbino
Department of Medicine, Division of Infectious Diseases, Central Laboratory of Virology, University Hospitals of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
Am J Respir Crit Care Med 170:1197-203. 2004..These viruses were associated with high morbidity, particularly in lung transplant recipients...
